Dilated cardiomyopathy:
can it heal and can the heart recover?

Article written and reviewed by Dr Luca Moretti

Yes, dilated cardiomyopathy can improve substantially. With treatment of the cause and appropriate therapy, the ventricle can decrease in size and the ejection fraction can increase, sometimes returning to the normal range. This phenomenon is called reverse remodeling.
However, when cardiac function returns to normal, speaking of a "definitive cure" can be misleading. In many patients, it is more accurate to speak of remission, because the biological or genetic substrate may persist and cardiomyopathy may recur, especially if treatment is stopped or the factor that caused it reappears.

Recovery depends mainly on:

• the cause of the cardiomyopathy and whether it can be removed;
• the duration and severity of ventricular dysfunction before treatment;
• the response to heart failure treatment;
• the presence of myocardial fibrosis and arrhythmias;
• any genetic component and the gene involved;
• control of blood pressure, heart rate and other factors that increase the workload on the heart;
• adherence to treatment and follow-up over time.

Dilated cardiomyopathy is characterized by ventricular dilation and reduced systolic function that are not explained solely by loading conditions or coronary artery disease sufficient to account for the clinical picture. There are many possible causes, and the etiology itself helps determine how much the heart may recover.

What does it really mean when "the heart has returned to normal"?

When treatment works, the echocardiogram may show a reduction in ventricular volumes and an increase in ejection fraction. Symptoms, exercise capacity and natriuretic peptide levels may also improve. When the change is substantial, this is called reverse remodeling, a phenomenon generally associated with a better prognosis than persistent dilation and dysfunction.
In some patients the improvement is partial, whereas in others systolic function returns to the normal range. There is no ejection fraction threshold, however, that by itself proves that the cause of the disease has disappeared.

The heart may once again appear normal on imaging while still retaining biological vulnerability. This is particularly important in genetic forms and in some cardiomyopathies that reactivate when a triggering factor returns. For this reason, heart failure guidelines increasingly distinguish between simple improvement in ejection fraction and definitive cure.

Which forms may recover more easily?

The probability of recovery is greater when there is an identifiable and genuinely correctable cause. In tachycardia-induced cardiomyopathy, for example, effective control of the arrhythmia or heart rate can lead to substantial recovery of ventricular function over the following months. Alcoholic cardiomyopathy can also improve significantly with abstinence, especially when the damage has not become irreversible.
A similar principle applies to some forms related to cardiotoxic substances or treatments: eliminating or modifying the exposure, when clinically possible, can promote recovery together with cardiac therapy.

The concept of reversibility should not, however, become a rigid classification. Even genetic dilated cardiomyopathy can improve substantially with treatment, whereas an apparently acquired form may recover only partially. In some patients, genetic predisposition and environmental factors coexist, as occurs in some cardiomyopathies associated with alcohol or other myocardial stressors.

How long does it take to see improvement?

Reverse remodeling does not occur at the same pace in everyone. Improvement may begin in the first months after optimization of therapy and control of the cause, but ventricular function may continue to change over the following months. For this reason, the response is assessed with serial follow-up examinations, not with a single echocardiogram performed shortly after diagnosis.
The speed of recovery also depends on the cause. A cardiomyopathy caused predominantly by a tachyarrhythmia may show relatively rapid recovery after stable rhythm control, whereas other forms require longer or do not achieve complete normalization.

During follow-up, symptoms, blood pressure, heart rate, ECG, kidney function, biomarkers when indicated, and echocardiography are reassessed. Cardiac magnetic resonance imaging can add information on the presence of fibrosis and the myocardial substrate. An improvement in numerical values must always be interpreted together with the cause and arrhythmic risk.

Why medications should not be stopped when the ejection fraction improves

One of the most common mistakes is to think that a normalized ejection fraction automatically makes medications unnecessary. The TRED-HF trial showed that, in selected patients with apparently recovered dilated cardiomyopathy, gradual withdrawal of heart failure treatment led to relapse in about four out of ten people within six months. Long-term follow-up of the same cohort showed that the risk of recurrence remained high over the following years.
These findings strengthened the concept that recovery often represents a remission maintained by treatment rather than a definitive biological cure.

Guidelines therefore recommend not stopping on your own beta-blockers, drugs acting on the renin-angiotensin system, mineralocorticoid receptor antagonists, SGLT2 inhibitors or other prescribed therapies. The treatment actually required depends on the clinical situation and may be modified by the cardiologist, but normalization of function is not in itself a sufficient reason to stop treatment.

Recovery of function and risk of relapse

A person who has recovered ventricular function generally has a better outlook than someone with persistent severe dysfunction, but the risk does not necessarily return to that of a person who has never had cardiomyopathy. New reductions in ejection fraction, arrhythmias or recurrence of symptoms may occur, sometimes in relation to infections, hypertension, pregnancy, recurrence of an arrhythmia or reduction of therapy.
In genetic forms, arrhythmic risk may also not perfectly track changes in ejection fraction: some genotypes have a significant arrhythmic profile even when systolic function is not severely reduced.

For this reason, follow-up should continue even when the echocardiogram has returned to normal. New shortness of breath, reduced exercise capacity, rapid weight gain, swelling of the legs, persistent palpitations or episodes of syncope require reassessment. Significant chest pain, severe shortness of breath or loss of consciousness require urgent medical attention.

Frequently asked questions about recovery from dilated cardiomyopathy

Can dilated cardiomyopathy heal completely?
A very substantial normalization of cardiac dimensions and function can occur, but it is often more accurate to speak of remission or reverse remodeling than of definitive cure.

How long does it take for the ejection fraction to improve?
Improvement may begin in the first months, but the timing is highly variable and it may continue during follow-up.

If the ejection fraction returns to normal, can I stop my medications?
Not on your own. Withdrawal of therapy is associated with a significant risk of relapse and should only be considered by the specialist.

Which forms may be more reversible?
Forms in which a correctable causal factor is removed, such as a persistent tachyarrhythmia or alcohol exposure, may show substantial recovery, but there is no individual guarantee.

Can genetic cardiomyopathy improve?
Yes. Genetic forms can also show reverse remodeling; however, the genotype may continue to influence arrhythmic risk and the likelihood of relapse.